Randomized Open Label PhII Trial of Neoadjuvant Trastuzumab Emtansine (Te) in Combination w/Lapatinib (L) Followed by Abraxane (A) Compared w/Trastuzumab Plus Pertuzumab Followed by Paclitaxel in Her 2 Neu Over-Expressed Breast Cancer Patients

Trial Profile

Randomized Open Label PhII Trial of Neoadjuvant Trastuzumab Emtansine (Te) in Combination w/Lapatinib (L) Followed by Abraxane (A) Compared w/Trastuzumab Plus Pertuzumab Followed by Paclitaxel in Her 2 Neu Over-Expressed Breast Cancer Patients

Recruiting
Phase of Trial: Phase II

Latest Information Update: 25 Oct 2016

At a glance

  • Drugs Trastuzumab emtansine (Primary) ; Lapatinib; Paclitaxel; Pertuzumab; Trastuzumab
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Acronyms TEAL
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 07 Oct 2015 Added pertuzumab to drug descriptors and modified the treatment table, title and purpose to reflect the protocol changes reported by the ClinicalTrials.gov.
    • 07 Oct 2015 Planned End Date changed from 1 Jun 2016 to 1 Jun 2017, as reported by ClinicalTrial.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top